Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 10/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677160 | 1.00 | PDE3B (0.46) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5677201 | 0.89 | PDE3B (0.48) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5681007 | 0.89 | PDE3B (0.48) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5677191 | 0.89 | PDE3B (0.48) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5677182 | 0.89 | PDE3B (0.48) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5679134 | 0.82 | PDE3B (0.52) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5679128 | 0.82 | PDE3B (0.52) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5677163 | 0.78 | PDE3A (0.43) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5681590 | 0.76 | MAPT (0.53) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 | |
| SCHEMBL5681587 | 0.76 | MAPT (0.53) | PDE3BPDE3AMAPTSMN1; SMN2TNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265871-B1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6699868-B2 | INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE | ORION CORPORATION (FI) | 2004-03-02 | — | — | US | disclosed |
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | ORION CORPORATION (FI) | 2003-08-21 | — | — | US | disclosed |
| EP-1265871-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068611-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | FABP3, TNNI3, TNNT2 | PDE3B 1154/4885PDE3A 667/4885MAPT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.